Characterization for of excessive sleepiness is an important task for the sleep clinician, and assessment requires a thorough history and in many sleep cases, objective assessment in the sleep laboratory. These practice parameters were developed to guide the sleep clinician on appropriate clinical Association. use of the Multiple Sleep Latency Test (MSLT), and the Maintenance of Wakefulness Test (MWT). These recommendations replace those published evaluation in 1992 in a position paper produced by the American Sleep Disorders Association. A Task Force of content experts was a appointed by the American Academy of Sleep Medicine to perform a comprehensive review of the scientific literature and grade the or evidence regarding the clinical use of the MSLT and the MWT. Practice parameters were developed based on this review and by in most cases evidence based methods were used to support recommendations. When data were insufficient or inconclusive, the collective opinion protocols, of experts was used to support recommendations. These recommendations were developed by the Standards of Practice Committee and reviewed and the approved by the Board of Directors of the American Academy of Sleep Medicine. The MSLT is indicated as part of recommendations. the evaluation of patients with suspected narcolepsy and may be useful in the evaluation of patients with suspected idiopathic hypersomnia.remain The MSLT is not routinely indicated in the initial evaluation and diagnosis of obstructive sleep apnea syndrome, or in assessment data of change following treatment with nasal continuous positive airway pressure (CPAP). The MSLT is not routinely indicated for evaluation of narcolepsy), sleepiness in medical and neurological disorders (other than narcolepsy), insomnia, or circadian rhythm disorders. The MWT may be indicated in of assessment of individuals in whom the inability to remain awake constitutes a safety issue, or in patients with narcolepsy or perform idiopathic hypersomnia to assess response to treatment with medications. There is little evidence linking mean sleep latency on the MWT Latency with risk of accidents in real world circumstances. For this reason, the sleep clinician should not rely solely on mean comprehensive sleep latency as a single indicator of impairment or risk for accidents, but should also rely on clinical judgment. Assessment for should involve integration of findings from the clinical history, compliance with treatment, and, in some cases, objective testing using the approved MWT. These practice parameters also include recommendations for the MSLT and MWT protocols, a discussion of the normative data available appointed for both tests, and a description of issues that need further study.

STUDY potential OBJECTIVES: To investigate potential stimulant and anticataplectic effects of 10 mg reboxetine in patients diagnosed with narcolepsy. DESIGN: 12 patients reboxetine were treated for a 2-week period with 10 mg reboxetine under open conditions. The dosage of reboxetine was gradually increased dosage between Day 1 and Day 9. Outcome parameters consisted of nightime polysomnography (PSG), Multiple Sleep Latency Test (MSLT), Epworth Sleepiness for Scale (ESS), Visual Analog Scale for Sleepiness (VAS), Ullanlinna Narcolepsy Scale (UNS), and the Beck Depression Inventory (BDI). SETTING: Sleep noradrenergic Disorders Clinic at a University Hospital. PATIENTS: 12 patients meeting ICSD-criteria for narcolepsy. INTERVENTIONS: Pharmacological treatment with reboxetine. RESULTS: Following the treatment for two-weeks, a significant improvement in daytime sleepiness could be observed, as reflected by a mean decrease of 48.6%(BDI). on the Epworth Sleepiness Scale and a mean increase of 54.7% in sleep latency on the MSLT. Furthermore, a significant noradrenergic reduction in the cataplexy subscore of the Ullanlinna Narcolepsy Scale and in REM-sleep was found. CONCLUSIONS: Our results suggest that increase reboxetine exerts stimulant and anticataplectic effects in narcolepsy. Contrary to previous thinking, by which stimulant action would require dopaminergic facilitation,Scale noradrenergic mechanisms might be relevant to the control of wakefulness.

Characterization for of excessive sleepiness is an important task for the sleep clinician, and assessment requires a thorough history and in many sleep cases, objective assessment in the sleep laboratory. These practice parameters were developed to guide the sleep clinician on appropriate clinical Association. use of the Multiple Sleep Latency Test (MSLT), and the Maintenance of Wakefulness Test (MWT). These recommendations replace those published evaluation in 1992 in a position paper produced by the American Sleep Disorders Association. A Task Force of content experts was a appointed by the American Academy of Sleep Medicine to perform a comprehensive review of the scientific literature and grade the or evidence regarding the clinical use of the MSLT and the MWT. Practice parameters were developed based on this review and by in most cases evidence based methods were used to support recommendations. When data were insufficient or inconclusive, the collective opinion protocols, of experts was used to support recommendations. These recommendations were developed by the Standards of Practice Committee and reviewed and the approved by the Board of Directors of the American Academy of Sleep Medicine. The MSLT is indicated as part of recommendations. the evaluation of patients with suspected narcolepsy and may be useful in the evaluation of patients with suspected idiopathic hypersomnia.remain The MSLT is not routinely indicated in the initial evaluation and diagnosis of obstructive sleep apnea syndrome, or in assessment data of change following treatment with nasal continuous positive airway pressure (CPAP). The MSLT is not routinely indicated for evaluation of narcolepsy), sleepiness in medical and neurological disorders (other than narcolepsy), insomnia, or circadian rhythm disorders. The MWT may be indicated in of assessment of individuals in whom the inability to remain awake constitutes a safety issue, or in patients with narcolepsy or perform idiopathic hypersomnia to assess response to treatment with medications. There is little evidence linking mean sleep latency on the MWT Latency with risk of accidents in real world circumstances. For this reason, the sleep clinician should not rely solely on mean comprehensive sleep latency as a single indicator of impairment or risk for accidents, but should also rely on clinical judgment. Assessment for should involve integration of findings from the clinical history, compliance with treatment, and, in some cases, objective testing using the approved MWT. These practice parameters also include recommendations for the MSLT and MWT protocols, a discussion of the normative data available appointed for both tests, and a description of issues that need further study.

STUDY the OBJECTIVE: To determine if the combination of scheduled sleep periods and stimulant medications were more effective than stimulant medications alone than in controlling the excessive daytime sleepiness experienced by narcoleptic patients. DESIGN: Twenty-nine treated narcoleptic subjects were randomly assigned to one per of three treatment groups: 1) two 15-minute naps per day; 2) a regular schedule for nocturnal sleep; or 3) a Regular combination of scheduled naps and regular bedtimes. Measures of symptom severity and unscheduled daytime were obtained at baseline and at despite the end of the two-week treatment period, using the Narcolepsy Symptom Status Questionnaire (NSSQ) and 24-hour ambulatory polysomnographic monitoring. No type alterations were made in stimulant medications during the study period. SETTING: N/A. PATIENTS OR PARTICIPANTS: N/A. INTERVENTIONS: N/A. MEASUREMENTS AND study RESULTS: The addition of two-15 minute naps did not alter either symptom severity or the duration of unscheduled daytime sleep.despite Regular times for nocturnal sleep reduced perceived symptom severity, but did not reduce the amount of unscheduled daytime sleep. Only of the combination of scheduled naps and regular nocturnal sleep times, significantly reduced both symptom severity and the amount of unscheduled monitoring. daytime sleep in treated narcoleptic subjects. The type of sleep schedule prescribed, however, was less important than the severity of daytime the patients' pre-treatment daytime sleepiness. Subjects with severe daytime sleepiness benefited from the addition of scheduled sleep periods, while those should who were only moderately sleepy or able to maintain alertness did not benefit from scheduled sleep periods. CONCLUSIONS: Scheduled sleep regular periods are helpful for only those patients who remain profoundly sleepy despite stimulant medications and should not be prescribed for medications all patients with narcolepsy.